Abivax Shares Climb 5.55% in Chicago During Digestive Disease Week
The French biotech progresses to €101.80 in mid-session on Monday, marking a 5.55% increase from the last close of €96.45. The movement occurs during the Digestive Disease Week held in Chicago until May 5. The year-over-year performance remains exceptional at +1469%.
The Stock Rebounds During the Chicago Scientific Congress
Abivax advances 5.55% in session to €101.80, while the CAC 40 drops 0.49% at the same time. The rebound takes place during the Digestive Disease Week, where the company presents nine scientific abstracts dedicated to obefazimod, its candidate treatment for ulcerative colitis. These presentations cover the efficacy, tolerance, and patient feedback from the phase 3 ABTECT program, as well as preclinical models of antifibrotic activity. The stock had dropped 2.93% last Wednesday to €92.75 as the event approached. Financially, the company indicated in its third quarter 2025 release that it had cash visibility until the fourth quarter of 2027, following an ADS offering that extended its financial autonomy.
The Stock Returns to Its 50-Day Moving Average
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The price is almost at its 50-day moving average of €102.08, after having dipped below it at the end of April. The 200-day moving average at €86.54 remains well below the current price, confirming the underlying bullish trend. The RSI at 42 indicates a market without directional excess, contrasting with the volatility measured at 56.21 over a month. Within the Bollinger Bands (€89.20 to €110.60), the stock is positioned at 59% of the range, showing no visible tension. The next technical threshold identified is at €109.60, with the current support at €88.80. The next financial calendar event is the release of the first quarter 2026 results, scheduled for June 1.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
